HC Wainwright Has Bearish Outlook for AnaptysBio Q1 Earnings

AnaptysBio, Inc. (NASDAQ:ANAB) – Stock analysts at HC Wainwright reduced their Q1 2025 earnings per share (EPS) estimates for shares of AnaptysBio in a research report issued on Wednesday, February 12th. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will post earnings of ($1.56) per share for the quarter, down from their previous forecast of ($1.44). HC Wainwright currently has a “Neutral” rating and a $19.00 price target on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share. HC Wainwright also issued estimates for AnaptysBio’s Q2 2025 earnings at ($1.65) EPS, Q3 2025 earnings at ($1.74) EPS, Q4 2025 earnings at ($1.85) EPS, FY2025 earnings at ($6.79) EPS, FY2026 earnings at ($6.19) EPS, FY2027 earnings at ($10.60) EPS and FY2028 earnings at ($10.49) EPS.

A number of other research analysts have also weighed in on the stock. Wolfe Research began coverage on shares of AnaptysBio in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $25.00 price target on the stock. Wedbush reaffirmed an “outperform” rating and issued a $40.00 price target on shares of AnaptysBio in a research note on Wednesday, February 12th. BTIG Research cut AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. Guggenheim decreased their price objective on AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. Finally, JPMorgan Chase & Co. lowered their target price on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a research note on Thursday, December 19th. Four research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, AnaptysBio has an average rating of “Moderate Buy” and an average target price of $37.45.

AnaptysBio Stock Performance

AnaptysBio stock opened at $19.78 on Monday. The stock has a market capitalization of $601.91 million and a P/E ratio of -3.25. AnaptysBio has a 1 year low of $12.21 and a 1 year high of $41.31. The company’s fifty day moving average price is $15.71 and its 200 day moving average price is $25.54.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC boosted its holdings in AnaptysBio by 131.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 1,531 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of AnaptysBio during the fourth quarter worth about $40,000. Values First Advisors Inc. purchased a new position in shares of AnaptysBio in the third quarter valued at approximately $49,000. nVerses Capital LLC grew its holdings in shares of AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 1,400 shares in the last quarter. Finally, AlphaQuest LLC increased its stake in AnaptysBio by 1,891.5% during the 4th quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company’s stock worth $59,000 after buying an additional 4,237 shares during the period.

Insider Activity

In other news, Director Ecor1 Capital, Llc bought 65,184 shares of the business’s stock in a transaction on Monday, December 30th. The shares were bought at an average price of $12.92 per share, with a total value of $842,177.28. Following the completion of the transaction, the director now directly owns 7,860,180 shares in the company, valued at $101,553,525.60. This trade represents a 0.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 33.70% of the company’s stock.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.